| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 58.5MM | +14% |
| Gross Profit | 52.4MM | - |
| Cost Of Revenue | 6.1MM | +53% |
| Operating Income | 7.9MM | +54% |
| Operating Expenses | 18.1MM | +27% |
| Net Income | 1.4MM | -19% |
| R&D | 9.2MM | -8% |
| G&A | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common stock and approximately $8.9 millionTotal debt reduced since December 31, 2023 is approximately $41.8 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled thera
Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be vulnerable to their...
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through December 31, 2024Christopher Prentiss appointed Chief Financial Officer, effective April 22, 2024 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lu
In this article, we will take a detailed look at Jim Cramer Says You Should Avoid These 11 Stocks. For a quick overview of such stocks, read our article Jim Cramer Says You Should Avoid These 5 Stocks. Jim Cramer in his latest program took a jab at the Department of Justice and Washington authorities in general, calling regulators […]
Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumpsSubjects utilizing inhaled insulin experienced a 22% decrease in mean glucose excursions in the first two hours compared to the standard of care17-week primary endpoint results will be presented during a 90-minute symposium at the American Diabetes Association’s Scientific Sessions in June DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 11, 202
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that new clinical data from the I
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will be participating at upcoming conferences. Leerink Partners Global Biopharma Conference 2024 – Investor Meetings, Monday, March 11, 2024 Oppenheimer 34th Annual Healthcare MedTech & Services Confere
Celebrations may be in order for MannKind Corporation ( NASDAQ:MNKD ) shareholders, with the analysts delivering a...
MannKind ( NASDAQ:MNKD ) Full Year 2023 Results Key Financial Results Revenue: US$199.0m (up 99% from FY 2022). Net...